Pulmonary infections and exacerbations are all too common among people with cystic fibrosis (CF), and the use of antibiotics (ABX) is universal. Most CF clinicians are aware that improper ABX exposure can lead to resistance, but what do they know about the current associations between pharmacodynamic targets and clinical outcomes? People with CF may have ABX clearance and volume of distribution that are different from those without the disease — but how does that translate into altered dosing regimens? What changes does treatment with highly effective CFTR modulators make in the safety and efficacy of commonly prescribed ABX?
These are some of the questions Dr. Andrea Hahn, assistant professor of pediatrics and infectious disease specialist at Children’s National Hospital and George Washington University School of Medicine and Health Sciences, discusses in her analysis of the key literature in this issue of eCysticFibrosis Review.
Assistant Professor of Pediatrics
Infectious Disease Specialist
Children’s National Medical Center
George Washington University School of Medicine and Health Sciences
Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD
Clinical Nurse
Pediatric Clinic Coordinator
Johns Hopkins Cystic Fibrosis Center
Baltimore, MD
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: September 16, 2020
Expiration date: September 15, 2022